Børresen-Dale AL - Search Results

1

A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide.

Glynn SA, Boersma BJ, Howe TM, Edvardsen H, Geisler SB, Goodman JE, Ridnour LA, Lønning PE, Børresen-Dale AL, Naume B, Kristensen VN, Chanock SJ, Wink DA, Ambs S. Glynn SA, et al. Clin Cancer Res. 2009 Jun 15;15(12):4165-73. doi: 10.1158/1078-0432.CCR-09-0119. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509150 Free PMC article.

2

Primary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome.

Aas T, Geisler S, Paulsen T, Børresen-Dale AL, Varhaug JE, Lønning PE, Akslen LA. Aas T, et al. Acta Oncol. 1996;35 Suppl 5:5-8. doi: 10.3109/02841869609083960. Acta Oncol. 1996. PMID: 9142957

3

Absence of p21 expression is associated with abnormal p53 in human breast carcinomas.

Ellis PA, Lonning PE, Borresen-Dale A, Aas T, Geisler S, Akslen LA, Salter I, Smith IE, Dowsett M. Ellis PA, et al. Br J Cancer. 1997;76(4):480-5. doi: 10.1038/bjc.1997.413. Br J Cancer. 1997. PMID: 9275025 Free PMC article.

4

Improved electrophoretic separation of polymorphic short tandem repeats in agarose gels using bis-benzimide.

Kristensen VN, Børresen-Dale AL. Kristensen VN, et al. Biotechniques. 1997 Oct;23(4):634-6. doi: 10.2144/97234bm18. Biotechniques. 1997. PMID: 9343680 Free article. No abstract available.

5

A rare CYP19 (aromatase) variant may increase the risk of breast cancer.

Kristensen VN, Andersen TI, Lindblom A, Erikstein B, Magnus P, Børresen-Dale AL. Kristensen VN, et al. Pharmacogenetics. 1998 Feb;8(1):43-8. doi: 10.1097/00008571-199802000-00006. Pharmacogenetics. 1998. PMID: 9511180

6

High-throughput screening for known mutations by automated analysis of single sequencing reactions.

Kristensen T, Kristensen VN, Børresen-Dale AL. Kristensen T, et al. Biotechniques. 1998 May;24(5):832-5. doi: 10.2144/98245dt04. Biotechniques. 1998. PMID: 9591134 Free article.

7

CYP17 and breast cancer risk: the polymorphism in the 5' flanking area of the gene does not influence binding to Sp-1.

Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lønning PE, Erikstein B, Kåresen R, Gabrielsen OS, Børresen-Dale AL. Nedelcheva Kristensen V, et al. Cancer Res. 1999 Jun 15;59(12):2825-8. Cancer Res. 1999. PMID: 10383140

8

Genetic variants of CYP19 (aromatase) and breast cancer risk.

Kristensen VN, Harada N, Yoshimura N, Haraldsen E, Lonning PE, Erikstein B, Kåresen R, Kristensen T, Børresen-Dale AL. Kristensen VN, et al. Oncogene. 2000 Mar 2;19(10):1329-33. doi: 10.1038/sj.onc.1203425. Oncogene. 2000. PMID: 10713674

9

Molecular epidemiology of breast cancer: genetic variation in steroid hormone metabolism.

Kristensen VN, Borresen-Dale AL. Kristensen VN, et al. Mutat Res. 2000 Apr;462(2-3):323-33. doi: 10.1016/s1383-5742(00)00018-1. Mutat Res. 2000. PMID: 10767642 Review.

10

Screening breast cancer patients for Norwegian ATM mutations.

Laake K, Vu P, Andersen TI, Erikstein B, Kåresen R, Lonning PE, Skovlund E, Børresen-Dale AL. Laake K, et al. Br J Cancer. 2000 Dec;83(12):1650-3. doi: 10.1054/bjoc.2000.1519. Br J Cancer. 2000. PMID: 11104561 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

508 results

Search Page